Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia

NCT00688896 is registered in ClinicalTrials.gov with Akros Pharma Inc. as lead sponsor.

NCT NCT00688896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00688896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia
Lead sponsor
Akros Pharma Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2002
Completion date
March 31, 2004
Enrollment
155 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type ii hyperlipidemia